Volume : 08, Issue : 10, October – 2021
Title:
30.ANALYSIS OF EFFICACY LEVELS COMPATIBLE WITH ITS REQUIREMENTS, A COMPARISON OF SINOPHARM VS SINOVAC COVID-19 VACCINES
Authors :
Prof. Dr. Ghazala Rubi, Dr. Shagufta Nasreen, Taha Javaid, Prof. Dr. Fozia Farzana, Prof. Dr. Muhammad Yasoob, Dr. Javaid, Dr. Muna Malik
Abstract :
The ongoing COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in significant death and morbidity rates around the globe. SARS-CoV-2 infection has been linked to 43.3 million confirmed cases worldwide, killing 1.15 million people. Physical separation, quarantine, and isolation were successful in minimizing the number of individuals who became sick during the epidemic, but the lack of immunity in the community makes them vulnerable to further waves of SARS-CoV-2 infection. Elderly persons (those 60 and older) and those with pre-existing medical problems are particularly vulnerable. , .
Material and Methods: In this observation study, people who were vaccinated with sinopharm vaccine and sinovac vaccine were included to see the response of vaccine in the body. The aim of the study was to compare the rise in the antibody level after 2 doses of two different COVID-19 vaccines i.e sinopharm and sinovac. Initially, in this pilot study, 40 people were included randomly from our health care team, after proper informed consent regarding the study. All the details regarding the study were shared and written informed consent was taken.
Results: Among total 40 people were involved, male were 21 of 40 (52.5%) and female were 19 of 40 (47.5%). Most of the individuals were doctors (26 of 40, 65%). Mean age, weight, height and body mass index (BMI) are also shown below.
Conclusion: This study was to report the response of people of Pakistan toward sinopharm and sinoVac vaccines in terms of COVID antibody level. Response of the body was around 40 to 50% for sinopharm and 50 to 70 percent towards CoronaVac vaccine. Further data collection is being done to improve sample size and better outcome.
Cite This Article:
.Please cite this article in press Ghazala Rubi et al, Analysis Of Efficacy Levels Compatible With Its Requirements, A Comparison Of Sinopharm Vs Sinovac Covid-19 Vaccines ., Indo Am. J. P. Sci, 2021; 08(10).
Number of Downloads : 10
References:
1. Walker PGT, Whittaker C, Watson OJ, et al. The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries. Science 2020; 369: 413–22
2. WHO. Coronavirus disease (COVID-19) situation report – 163. Geneva: World Health Organization, 2020. https://www.who.int/ docs/default-source/coronaviruse/situation-reports/20200701-covid19-sitrep-163.pdf?sfvrsn=c202f05b_2
3. Flaxman S, Mishra S, Gandy A, et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature 2020; 584: 257–61
4. Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis 2020; 26: 1470–77
5. Walker PGT, Whittaker C, Watson OJ, et al. The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries. Science 2020; 369: 413–22
6. WHO. Coronavirus disease (COVID-19) situation report – 163. Geneva: World Health Organization, 2020. https://www.who.int/ docs/default-source/coronaviruse/situation-reports/20200701-covid19-sitrep-163.pdf?sfvrsn=c202f05b_2
7. Flaxman S, Mishra S, Gandy A, et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature 2020; 584: 257–61
8. Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2. Emerg Infect Dis 2020; 26: 1470–77
9. WHO. Draft landscape of COVID-19 candidate vaccines. Geneva: World Health Organization, Oct 19, 2020. https://www.who.int/ publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
10. Corey L, Mascola JR, Fauci AS, Collins FS. A strategic approach to COVID-19 vaccine R&D. Science 2020; 368: 948–50.
11. Graham BS. Rapid COVID-19 vaccine development. Science 2020; 368: 945–46
12. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020; 396: 467–78.
13. Gao Q, Bao L, Mao H, Wang L, Qin C. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 2020: 369: 77–81.
14. Wang Z., Schmidt F., Weisblum Y., Muecksch F., Barnes C.O., Finkin S. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021;592:616. doi: 10.1038/s41586-021-03324-6.
15. Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181-192. doi:10.1016/S1473-3099(20)30843-4.
16. Wu Z, Hu Y, Xu M, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(6):803-812. doi:10.1016/S1473-3099(20)30987-7
17. Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39-51. doi:10.1016/S1473-3099(20)30831-8
18. Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. Lancet. 2020;395:1014–1015
19. Jahromi M, Al Sheikh MH. Partial protection of Sinopharm vaccine against SARS COV2 during recent outbreak in Bahrain. Microb Pathog. 2021;158:105086. doi:10.1016/j.micpath.2021.105086.